Ghrelin and Obestatin in CKD Children
キーワード
概要
説明
This is a cross-sectional case-control study. Between January 2013 and June 2015 children and adolescents aged 5-20 years, referred to the Pediatric Nephrology, Dialysis and Transplant Unit of Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico - Milan, Italy were enrolled. Subjects with CKD stages II-V under conservative treatment (CKD-CT), or undergoing hemodialysis treatment (CKD-HD), or being renal transplant recipients (RTx) were included in the study. Data about age, primary renal disease and concomitant medications were collected for each subject.
CKD stages were defined using the K/DOQI criteria of the US National Kidney Foundation.
Control subjects were outpatients of the Pediatric Surgery Unit of the Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico - Milan, Italy, aged 1-20 years, who underwent a blood sample collection before a surgical intervention for the treatment of minor diseases that did not impair renal or endocrine function (i.e. phimosis, hydrocele, inguinal hernia).
Biochemical and hormonal parameters Blood samples were collected between 7:00 and 8:00 a.m. after an overnight fast, and before dialysis in CKD-HD patients. Routine biochemical parameters [creatinine, urea] were measured in all subjects. Glomerular filtration rate was estimated (eGFR) by the Schwartz formula, with k = 0.413, as appropriate for standardized creatinine.
In all subjects, plasma AG and UAG concentrations were measured by the Human Acylated / Unacylated Ghrelin ELISA kit (BioVendor, Laboratorni Medicina a.s., Brno, Czech Republic) according to manufacture procedures, and AG/UAG ratio was calculated. Serum obestatin concentrations were determined using the Human Obestatin ELISA kit (BioVendor, Laboratorni Medicina a.s., Brno, Czech Republic).
日付
| 最終確認済み: | 04/30/2017 |
| 最初に提出された: | 05/24/2017 |
| 提出された推定登録数: | 05/27/2017 |
| 最初の投稿: | 05/30/2017 |
| 最終更新が送信されました: | 05/27/2017 |
| 最終更新日: | 05/30/2017 |
| 実際の研究開始日: | 12/31/2012 |
| 一次完了予定日: | 06/29/2015 |
| 研究完了予定日: | 06/29/2015 |
状態または病気
介入/治療
Other: none intervention
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| CKD-CT subjects with CKD stages II-V under conservative treatment | |
| CKD-HD subjects with CKD stage V on hemodialysis | |
| RTx renal transplant renal transplant recipients | |
| Controls control subjects |
適格基準
| 研究の対象となる年齢 | 5 Years に 5 Years |
| 研究に適格な性別 | All |
| サンプリング方法 | Probability Sample |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: - the CKD-HD patients should have been on hemodialysis treatment for at least 3 months - the RTx patients should have received renal transplantation at least 6 months before Exclusion Criteria: - treatment with growth hormone - the presence of neurologic disability or syndromic diseases affecting per se food intake - for controls: they should have no history of chronic diseases and should not receive any medication. They should be on unrestricted diet. |
結果
主な結果の測定
1. AG concentrations by ELISA kit on plasma samples [January 2013-June 2015]
2. UAG concentrations by ELISA kit on plasma samples [January 2013-June 2015]
3. Obestatin concentrations by ELISA kit on serum samples [January 2013-June 2015]
